MMMasayuki Matsuda

Masayuki Matsuda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Masayuki Matsuda has a total of 88 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Multifocal Fibrosclerosis with Hypertrophic Pachymeningitis and a Soft Tissue Mass around the Thoracic Vertebral Bodies: A Case Report with Review of the Literature

    by Mitsuto Sato, Minori Kodaira, Wataru Ishii, Michitaka Nakagawa, Dai Kishida, Daigo Miyazaki, Yasuhiro Shimojima, Masayuki Matsuda, Takeshi Uehara, Shu-Ichi Ikeda

    Multifocal fibrosclerosis is the term used to represent a combination of similar fibrous lesions occurring at different anatomical sites. We herein report a hypertrophic pachymeningitis patient with a soft tissue mass around the thoracic vertebral bodies. A histopathological analysis of the biopsied tissues from both lesions showed dense fibrosis and a marked infiltration of lymphocytes and plasma cells, which lead to the diagnosis of multifocal fibrosclerosis. This pathological condition closely resembles that of IgG4-related disease and is a very rare combination of manifestations. Our case suggests that hypertrophic pachymeningitis patients need to also undergo a whole body examination.


  • Open Access

    Marked shrinkage of amyloid lymphadenopathy after an intensive chemotherapy in a patient with IgM-associated AL amyloidosis

    by Ko-Ichi Tazawa, Nagaaki Katoh, Yasuhiro Shimojima, Masayuki Matsuda, Shu-Ichi Ikeda

    A male patient with primary AL amyloidosis who had been suffering from systemic lymphadenopathy with IgMkappa-type M-proteinemia received two courses of VAD and high-dose melphalan with in vivo elimination of CD20(+) cells using rituximab followed by autologous peripheral blood stem cell transplantation. Four years after complete hematological remission he showed marked reduction in size of the amyloid-laden lymph nodes. Deposits of AL amyloid may regress from the tissue if the chemotherapy succeeds in persistent inhibition of the production of an amyloidogenic immunoglobulin light chain.


  • Marked shrinkage of amyloid lymphadenopathy after an intensive chemotherapy in a patient with IgM-associated AL amyloidosis

    by Ko-Ichi Tazawa, Nagaaki Katoh, Yasuhiro Shimojima, Masayuki Matsuda, Shu-Ichi Ikeda

    A male patient with primary AL amyloidosis who had been suffering from systemic lymphadenopathy with IgMkappa-type M-proteinemia received two courses of VAD and high-dose melphalan with in vivo elimination of CD20(+) cells using rituximab followed by autologous peripheral blood stem cell transplantation. Four years after complete hematological remission he showed marked reduction in size of the amyloid-laden lymph nodes. Deposits of AL amyloid may regress from the tissue if the chemotherapy succeeds in persistent inhibition of the production of amyloidogenic immunoglobulin light chains.


  • Open Access

    Nephrotic Syndrome Due to Primary Systemic AL Amyloidosis, Successfully Treated with VAD (Vincristine, Doxorubicin and Dexamethasone) Alone

    by Masayuki Matsuda, Takahisa Gono, Nagaaki Katoh, Takuhiro Yoshida, Ko-Ichi Tazawa, Yasuhiro Shimojima, Wataru Ishii, Tomohisa Fushimi, Shu-Ichi Ikeda

    We report 3 patients with nephrotic syndrome ascribed to primary systemic AL amyloidosis that were successfully treated with VAD (vincristine, doxorubicin and dexamethasone) alone. M-protein in serum disappeared soon after VAD, and nephrotic syndrome gradually improved in parallel with a decrease in daily protein excretion in urine. Long-term follow-up of these patients showed neither relapse of nephrotic syndrome nor reappearance of M-protein. High-dose melphalan followed by autologous stem cell support is a standard therapy for primary systemic AL amyloidosis, but in high-risk cases for this treatment, such as elderly patients and those with multiple organ involvement, VAD might be a therapeutic option.


  • AL amyloidosis manifesting as systemic lymphadenopathy

    by Masayuki Matsuda, Takahisa Gono, Yasuhiro Shimojima, Takuhiro Yoshida, Nagaaki Katoh, Yoshinobu Hoshii, Toshiyuki Yamada, Shu-Ichi Ikeda

    We report three patients with AL amyloidosis manifesting as systemic lymphadenopathy, mainly in the cervical and supraclavicular regions. Histopathology of lymph nodes showed massive deposition of AL amyloid with no abnormal findings suggestive of lymphoproliferative disorders. Two of the patients were considered to be classifiable as primary systemic AL amyloidosis based on the presence of M-protein in serum and abnormal plasma cells or lymphoplasmacytoid cells in the bone marrow probably producing the precursor immunoglobulin, although no visceral organs were affected. The size of the involved lymph nodes in these two patients increased gradually, and one was treated with rituximab and VAD (vincristine, doxorubicin and dexamethasone) followed by high-dose melphalan with autologous peripheral blood stem cell transplantation (auto-PBSCT). The remaining patient showed no obvious change in the size of lymph nodes or detectable M-protein in serum. The prognosis of AL amyloidosis manifesting as lymphadenopathy is usually good as long as there are no hematological malignancies or rapid increases in the size of lymph nodes, but in cases of the systemic type, intensive chemotherapy, such as high-dose melphalan with auto-PBSCT, should be actively considered in order to avoid possible involvement of visceral organs.


  • Open Access

    Henoch–Schönlein purpura nephritis complicated by reversible posterior leukoencephalopathy syndrome

    by Daimei Sasayama, Yasuhiro Shimojima, Takahisa Gono, Kazuma Kaneko, Masayuki Matsuda, Shu-Ichi Ikeda

    We report a young female patient with Henoch–Schönlein purpura (HSP) nephritis complicated by reversible posterior leukoencephalopathy syndrome (RPLS). The patient suddenly showed generalized seizures and cortical blindness with severe hypertension due to renal insufficiency approximately 1 year after cessation of corticosteroid treatment for HSP nephritis. Magnetic resonance imaging (MRI) demonstrated bilateral abnormal signals mainly in the cerebellum and white matter of the occipital lobe. Clinical symptoms quickly improved in conjunction with disappearance of abnormal signals on brain MRI after starting control of hypertension and continuous hemodiafiltration with steroid pulse therapy and plasmapheresis. RPLS may be caused by vasculitis and also by hemodynamic change due to severe hypertension in HSP, particularly in patients with nephropathy. In such cases intensive treatment should be performed as soon as possible to avoid neurological sequelae.


  • Histopathological regression of systemic AA amyloidosis after surgical treatment of a localized Castleman's disease

    by Yasuhiro Shimojima, Yo-Ichi Takei, Ko-Ichi Tazawa, Takahisa Gono, Tomohisa Fushimi, Masayuki Matsuda, Yoshinobu Hoshii, Shu-Ichi Ikeda

    Previously, we reported a case of localized plasma cell type Castleman's disease with severe hepatomegaly and reactive systemic AA amyloidosis. The amyloid deposits were demonstrated in both the hepatic tissue and in the gastric mucosa. Surgical resection of an isolated extra-hepatic tumor was performed. The laboratory findings, including SAA and IL-6, remained within normal limits and the patient's hepatomegaly subsequently showed regression. Nine years after the operation, no amyloid deposition was seen in the gastric mucosa and the patient's liver was of normal size. Our findings with long-term follow up in this case indicated that the cessation of SAA production was the probable cause of histopathological regression of AA amyloid deposits in this patient.


  • Coexistence of Familial Mediterranean Fever and Behcet's Disease in a Japanese Patient

    by Masayuki Matsuda, Akinori Nakamura, Saiko Tsuchiya, Takuhiro Yoshida, Shiro Horie, Shu-Ichi Ikeda


  • Open Access

    Seronegative Sjögren syndrome with asymptomatic autoimmune sclerosing pancreatitis

    by Masayuki Matsuda, Hideaki Hamano, Takuhiro Yoshida, Takahisa Gono, Takeshi Uehara, Shigeyuki Kawa, Shu-Ichi Ikeda

    We report two elderly patients with seronegative Sjögren syndrome who showed benign swelling of the pancreas on computed tomography. Immunostaining of the biopsied lip tissue or serum examination confirmed an increase in production of IgG4, leading to a diagnosis of autoimmune sclerosing pancreatitis (ASP) as a cause of the asymptomatic swelling of the pancreas. Sicca symptoms and ASP spontaneously improved in one patient, and the other responded well to oral prednisolone. Seronegative Sjögren syndrome and ASP can concurrently occur as a clinical manifestation of the IgG4-related systemic disorder, particularly in elderly subjects, and, in such a case, corticosteroid may be a potent therapeutic option.


  • Open Access

    Remitting seronegative symmetrical synovitis with pitting oedema/polymyalgia rheumatica after infection with Mycoplasma pneumoniae

    by M Matsuda, Y Shimojima, T Gono, W Ishii, K Kaneko, M Yazaki, S-I Ikeda

    Here, we report clinical findings in four patients with RS3PE or PMR, or both, after infection with Mycoplasma pneumoniae. Increases in inflammatory reactions were seen in all patients, and the final diagnoses were RS3PE alone in patients 1 and 4, RS3PE associated with PMR in patient 2, and PMR alone in patient 3 (table 1).7, 8 None of the patients had a headache or blurred vision suggestive of associated temporal arteritis. Recent infection with M pneumoniae was confirmed in all patients by the presence of IgM antibody to this agent in the serum and the results of serial serological studies with or without a positive cold agglutination test. Serum IgM levels were within the normal limits in all patients, and none showed positive results for serological tests for other infectious agents or autoantibodies such as rheumatoid factor or antinuclear antibody. All patients were treated successfully with oral prednisolone, but two relapsed during the tapering of this drug.